Brian F. Mandell, MD, PhD Department of Rheumatic and Immunologic Diseases, Cleveland Clinic; Senior Associate Program Director, Internal Medicine Residency Program; Deputy Editor, Cleveland Clinic Journal of Medicine
Address: Brian F. Mandell, MD, PhD, Cleveland Clinic Journal of Medicine, NA32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mandelb@ccf.org
Dr. Mandell has indicated that he has received grant or research support from the Novartis, Smith-Kline, Centocor, Searle, and Merck corporations, and that this article discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still under investigation.
ABSTRACT
Advances in our understanding of the pathophysiology of rheumatic and immunologic diseases have led to improved therapies, such as tumor necrosis factor inhibitors and bisphosphonates. These drugs can not only alleviate symptoms but also alter the course of the disease. However, they also have significant potential side effects, which mandate, more than ever, correct diagnosis and vigilant monitoring for toxicity.
